Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia

Home | About RECERCAT | Contact

Català | Castellano

All of RECERCAT

By Communities &
Collections By Defense Date By Authors By Titles By Subject

This Collection

By Defense Date By Authors By Titles By Subject

Statistics

View Statistics All RECERCAT

My RECERCAT

Other repositories directory

RECERCAT Home > Universitat de Barcelona > IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer > Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) > View document

To access the full text documents, please follow this link: http://hdl.handle.net/2445/145039

dc.contributor.author	Cillóniz, Catia
dc.contributor.author	Calle, Cristina de la
dc.contributor.author	Dominedò, Cristina
dc.contributor.author	Garcia Vidal, Carolina
dc.contributor.author	Cardozo Espinola, Celia
dc.contributor.author	Gabarrús, Albert
dc.contributor.author	Marco Reverté, Francesc
dc.contributor.author	Torres Martí, Antoni
dc.contributor.author	Soriano Viladomiu, Alex
dc.date	2019-11-18T15:32:01Z
dc.date	2019-11-18T15:32:01Z
dc.date	2019-08-01
dc.date	2019-10-31T16:57:28Z
dc.identifier	2077-0383
dc.identifier	5767403
dc.identifier.uri	http://hdl.handle.net/2445/145039
dc.description	We aimed to analyze the impact of cefotaxime non-susceptibility on the 30-day mortality rate in patients receiving a third-generation cephalosporin for pneumococcal bacteremic pneumonia.We conducted a retrospective observational study of prospectively collected data from the Hospital Clinic of Barcelona. All adult patients with monomicrobial bacteremic pneumonia due to Streptococcus pneumoniae and treated with a third-generation cephalosporin from January 1991 to December 2016 were included. Risk factors associated with 30-day mortality were evaluated by univariate and multivariate analyses.During the study period, 721 eligible episodes were identified, and data on the susceptibility to cefotaxime was obtainable for 690 episodes. Sixty six (10%) cases were due to a cefotaxime non-susceptible strain with a 30-day mortality rate of 8%. Variables associated with 30-day mortality were age, chronic liver disease, septic shock, and the McCabe score. Infection by a cefotaxime non-susceptible S. pneumoniae did not increase the mortality rate.Despite the prevalence of cefotaxime, non-susceptible S. pneumoniae has increased in recent years. We found no evidence to suggest that patients hospitalized with bacteremic pneumonia due to these strains had worse clinical outcomes than patients with susceptible strains.
dc.format	10 p.
dc.format	application/pdf
dc.language	eng
dc.publisher	MPDI
dc.relation	Reproducció del document publicat a: https://doi.org/10.3390/jcm8081150
dc.relation	Journal of Clinial Medicine, 2019, vol. 8, num. 8
dc.relation	https://doi.org/10.3390/jcm8081150
dc.rights	cc by (c) Cillóniz et al., 2019
dc.rights	http://creativecommons.org/licenses/by/3.0/es/
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Pneumònia
dc.subject	Infeccions per pneumococs
dc.subject	Pneumonia
dc.subject	Pneumococcal infections
dc.title	Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion

Show simple item record

All of RECERCAT

This Collection

Statistics

My RECERCAT

Related documents

Other documents of the same author